Trial Profile
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Lenalidomide (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 12 May 2023 Results (n=110; between 2010 and 2015) assessing the safety and efficacy of cediranib with or without lenalidomide, in the treatment of iodine 131-refractory differentiated thyroid cancer, published in the Annals of Oncology.
- 24 Jun 2021 Status changed from active, no longer recruiting to completed.
- 22 Feb 2019 Planned primary completion date changed from 30 Sep 2018 to 1 Feb 2020.